Ann: Quarterly Activities Report, page-33

First 33 Last

Share
Profile

Follow
9for9

132 Posts.

13

29/07/22

20:03

Post #: 62821343
Share

Originally posted by xanax: ↑

My view:
As previously stated PAN will receive an scheme offer from IGO.
That cannot proceed without Board: Expert & Court appro. etc.
Therefore corporate games.
Managements job now is to extract the highest possible price.
As an expert cannot give an opinion on fair value in a ramp-up stage,
It is likely that Year end + 2/3 Q reports needed.
Therefore:
Make the last Q. results look ordinary.
How:
Only bring to account cash received.
Ignore receivables.
Expense everything against cash received.
Which makes costs look excessive.
However:
In the coming Q account for cash received, with the expenses in the last Q.
AISC drops: profits well up: re-rating each Q.
With a fair wind and a strengthening PoN and barring any Black Swan events:
Each Q. should exceed the previous.
Leaving IGO with a problem:
It's going to have to pay overs to get control:
Something it is not in its DNA.

Also, I would look for a scrip transaction, not cash, as I would prefer the tax liability at a time of my choosing not IGO's.

This is a bit simplistic but written for some of the younger players here.
As previously stated I'm a big believer in the Ni sector with 700K PAN & moving towards 1m. Also 1.1m POS with a view to move to 2m.
That's enough skin and anxiety (hence Xanax) in the game at this end of the market

cheers

xanax

Expand

Spot on summary Xanax but I find the single malt does the job for me - there will still be plenty of anxiety before the dust finally settles here but the potential positives have a good chance of delivering as good an outcome for holders as anything else in the nickel space - hence my buy sentiment

PAN Price at posting: 19.5¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

OJC

SPC to merge with Original Juice Co and Nature One Dairy

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

There are more pages in this discussion • 24 more messages in this thread...

First 33 Last

Add PAN (ASX) to my watchlist

Ann: Quarterly Activities Report, page-33

Top Stories

SPC to merge with Original Juice Co and Nature One Dairy

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News